# Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy

> **NCT00691704** · PHASE2 · COMPLETED · sponsor: **Cristina Gasparetto** · enrollment: 18 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Lenalidomide Induction
- **DRUG:** Sequential Maintenance Therapy

## Key facts

- **NCT ID:** NCT00691704
- **Lead sponsor:** Cristina Gasparetto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2012-12
- **Final completion:** 2014-05
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2014-08-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00691704

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00691704, "Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00691704. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*